Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.


TSXV:XRTX - Post by User

Comment by cybermanon Nov 12, 2020 3:10pm
121 Views
Post# 31886651

RE:RE:World Antiviral Congress

RE:RE:World Antiviral Congress

hiya KOkid, nemo, there is definitely good things happening or we wouldn't have been included in this event, can't wait for an update from mt. sinai trials which i thought we may have had before this event to further validate, my guess is we see it soon...

not aware of anything re financing etc...those things would be great for sure, just connecting dots based on what is public info, haven't even emailed the company ever, that may change as i'd love to read the speech from today, maybe they'll put on xrx website.

pretty confident overall, mostly, bids are growing and imo it's a bargain for the patient !

between the 3 of us here + moose there doesn't seen to be many other to wish good luck.

also, fwiw, from the terrapin website;

Evident with every viral pandemic including COVID-19, rapid deployment of compatible antiviral therapies is of paramount importance, particularly before a long-term strategy of a vaccine is possible.

Antivirals can prevent or control viral diseases from emerging diseases, respiratory infections, chronic diseases to virus-associated tumours.


Join us on this virtual congress to get up to speed and help accelerate your antiviral research from bench to patient.

 



KOkidneydisease wrote: Just looked at the invited companies list. I've never seen us in amongst such a high quality list of companies before. Hope this translates into a financing soon. Dr. Davidoff has made a huge amount of progress up to this point!!

Hey Cyberman, have you heard anything lately re: financing, licensing, royalties agmts? 

To be invited to this conference has to show some sort of advanced stage of preparation.


<< Previous
Bullboard Posts
Next >>